ACTC Shareholder Meeting Questions

[Joseph Exline]

1. How much does the possibility of a takeover worry you?

2. Is it ACT's intention to do all manufacturing and shipping of RPE cells for SMD in Marlborough, once it is ready for the market? Will ACT keep SMD in house?

3. Has Roslin received our cells yet and when can we expect them to begin the storaging/licensing of ACT's cells?

4. Will the cells at Roslin be purely undifferentiated hESCs? Or will they also store fully differentiated cells such as RPE or Mesenchymal?

5. Assuming the proxy for the r/s is approved, what will be the main criteria for determining the timing to implement the r/s?

[I have many other questions about the blood IND and how we are going to go about doing several trials at once (RPE, blood, mesenchymal, etc...), but I have a feeling all of this will be answered in the Roadmap that we were promised at the meeting.

[/I][/I]

I wouldn't count on it, if your wondering of something I would ask directly and specifically.

[Joseph Exline]

When will additional members be placed on the compensation committee and can shareholders review future revisions prior to implementation?
What are your thoughts on having a pool of replacement players for the AMD trials going forward in an effort to avoid obvious,foreseeable delays ?
Where is our CFO?....AGAIN?
Where is our road map?
China who?

[milachka]

I'd like an updated timeline for the ongoing trials: with target dates for each cohort!

[Superfeeed]

Keep em coming please.

[michaelbrom]

Roslin status..?

[Vzveteran]

What ever happened to the licensing deal with the Methodist Universities?

Update on Cirm and the NIH.

[GMAN]

what happened to exciting new BOD?

Korea update?

[Bogeyfree]

Just one for Dr. Lanza if he is at the meeting.

What do you think of Ruth McKernan and would you ever consider working for her?

Based on his reaction to the question, will tell us if Pfizer is in the running.

Bogeyfree

[jd56]

1. how many shares did you receive directly or indirectly
from the recent settlement via you involvement or partnership/owner
in one or more of the companies involved in the settlement.

2.will stock compensation also be reduced to reflect the r/s

3. if it takes four of more months to qualify for the nasdaq then how do you intend to defend
our share price while were still on the bb/otc. please be specific.

[JHam]

[/I][/I]

I wouldn't count on it, if your wondering of something I would ask directly and specifically.

When will additional members be placed on the compensation committee and can shareholders review future revisions prior to implementation?
What are your thoughts on having a pool of replacement players for the AMD trials going forward in an effort to avoid obvious,foreseeable delays ?
Where is our CFO?....AGAIN?
Where is our road map?
China who?

We should probably leave this thread to only questions for the meeting and not discussion. But I feel I should respond to your posts. Gary has already said the roadmap will be presented at the meeting. That really is the only reason I am considering goin to the meeting. He said "everyone" will be there. I took that to mean they would go over the roadmap in detail. Therefore, if we go all the way to Palm Springs and there is no roadmap, it would be like driving all the way to Wally World only for it to be closed. There would be shareholder outrage at the meeting as this is the main reason why many are attending.

Good question about the CFO!

[bo-bo241]

Will we ever get the chance to play BOCCE on the island?

[Lanza Paste]

I'd like to ask Dr. Lanza to elaborate on the fact that only 10% of the injected RPE cells survived. Does this concern him or was it anticipated? Is this similar to what he observed in the animal models? Is improving this survival rate a top priority and does he believe he has a solution on how to do so?

[twenty2]

I'd like to ask Dr. Lanza to elaborate on the fact that only 10% of the injected RPE cells survived. Does this concern him or was it anticipated? Is this similar to what he observed in the animal models? Is improving this survival rate a top priority and does he believe he has a solution on how to do so?

All very good questions, LP! And just to add:
Are any more modifications being considered regarding the Instrument that is used in the DELIVERY/INJECTION of the Cells into the Eye?
Will we seek patents on any new Delivery Process/Protocol, Or Instrument?

twenty2

[loki911]

What does ACTC anticipate as their competitive advantage to be for making the universal blood compared to what is being created by Douay? Is ten times the volume enough of an advantage to justify the stigma that goes along with hESC’s?

[AMGuy]

Three questions:
1. In the opinion of ACTC, what would be a productive or beneficial relationship with CIRM? What terms & conditions would be attractive to ACTC?
2. In regards to ACTCs universal blood development program, has the company had any consultations/discussions with the DOD, VA, DARPA, ect ?
3. When might we expect insiders (Rabin, Lanza, BOD, et al) to actually purchase shares of ACTC on the open market?

[rocky301]

What was ACT's logic in taking a Socius draw on DEC 15, 2011 when the pps was at .10?
Without it we would have ended the year with $11MM in cash so another reason must exist?
Knowing the Lancet info was forthcoming the draw could have easily been done at a pps that
would have taken approx. 50% less shares to cover.

The 10K incicates an additional 135MM shares possible in settlement shares. Does this include
all 3 of the major outstanding lawsuits of Camofi, Aronson and Gorton?

[twenty2]

Upon uplisting to the Nasdaq, when would you expect those Institutional/Healthcare Investors you talked to, to start taking positions (buy stock) in ACTC?
How can you be sure???

twenty2

[Lanza Paste]

I would also like to ask Gary what, "every large pharma with an ocular department is all over us right now" means in greater detail. It would be nice to know what sort of offers have been thrown at us so far. I'm pretty sure he won't give us specifics, but we could perhaps gauge the interest out there by how he handles the question.

[keybridge]

1) Discuss the state of existing liquidity; how will that cash be allocated; and when and under what type of financing arrangements does ACT expect to raise additional capitial;
2) What financial structure, parameters or goals does management expect for a JV;
3) How close is ACT to coming to terms for a JV;
4) What are the opinions of those in the institutional investor community about ACT;
5) How many more directors will ACT appoint to the board and what qualificatons are being considered for those seats;
6) Has the company considered hiring a general counsel;
7) Where does management see ACT in 5 to 10 years?


If I had just one big question to ask Gary: Please share your short and long-term vision for ACT?

[tradeup]

Does ACT need a graffiti-style mural painted at their headquarters... for, let's say 50MM shares?